Millendo Therapeutics

Ann Arbor, United States Founded: 2012 • Age: 14 yrs
Immune-mediated targeted therapies for cancer are developed.
Request Access

About Millendo Therapeutics

Millendo Therapeutics is a company based in Ann Arbor (United States) founded in 2012.. Millendo Therapeutics has raised $102.77 million across 5 funding rounds from investors including University of Michigan, Frazier Healthcare Partners and NEA. The company has 30 employees as of December 31, 2022. Millendo Therapeutics has completed 1 acquisition, including Alizé Pharma. Millendo Therapeutics operates in a competitive market with competitors including BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and Mereo BioPharma, among others.

  • Headquarter Ann Arbor, United States
  • Employees 30 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Atterocor Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $102.77 M (USD)

    in 5 rounds

  • Latest Funding Round
    $62 M (USD), Series B

    Jan 04, 2016

  • Investors
  • Employee Count
    30

    as on Dec 31, 2022

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Millendo Therapeutics
Headcount 10-50
Employee Profiles 7
Board Members and Advisors 11
Employee Profiles
People
Nicholas Maestas
VP, Strategy & Finance
People
Justin Trojanowski, CPA
Corporate Controller
People
Darrin Bomba
VP, Clinical Operations
People
Stephen Brady
President & CEO

Unlock access to complete

Board Members and Advisors
people
Drew M. Pardoll
Advisor
people
Geoff Nichol
Board Member
people
Benjamin F. Cravatt
Advisor
people
Mike Raab
Chairman, Board of Directors

Unlock access to complete

Funding Insights of Millendo Therapeutics

Millendo Therapeutics has successfully raised a total of $102.77M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $62 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series B — $62.0M
  • First Round

    (23 Apr 2012)

  • Investors Count 10
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2016 Amount Series B - Millendo Therapeutics Valuation New Enterprise Associates
Feb, 2013 Amount Private Equity Round - Millendo Therapeutics Valuation

investors

Feb, 2013 Amount Series A - Millendo Therapeutics Valuation 5AM Ventures , Frazier Healthcare Partners
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Millendo Therapeutics

Millendo Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include University of Michigan, Frazier Healthcare Partners and NEA. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments are offered to startups by NEA.
Founded Year Domain Location
Venture capital fund backed incubator focused on the healthcare startups
Founded Year Domain Location
Venture capital is directed toward healthcare companies by Longwood Fund.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Millendo Therapeutics

Millendo Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alizé Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Develop drugs, proteins and peptides for the treatment of metabolic and rare diseases
2007
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Millendo Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Millendo Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Millendo Therapeutics

Millendo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
ALX Oncology is focused on advancing cancer treatment therapies.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Millendo Therapeutics

Frequently Asked Questions about Millendo Therapeutics

When was Millendo Therapeutics founded?

Millendo Therapeutics was founded in 2012.

Where is Millendo Therapeutics located?

Millendo Therapeutics is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.

Is Millendo Therapeutics a funded company?

Millendo Therapeutics is a funded company, having raised a total of $102.77M across 5 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on Apr 23, 2012.

How many employees does Millendo Therapeutics have?

As of Dec 31, 2022, the latest employee count at Millendo Therapeutics is 30.

What does Millendo Therapeutics do?

Millendo Therapeutics was founded in 2012 in Ann Arbor, United States, within the biotechnology sector. Focus is placed on immune-mediated targeted therapies for cancer. The product pipeline is composed of TPST-1120, a PPARα antagonist used in hepatocellular carcinoma, cholangiocarcinoma, and renal cell carcinoma; TPST-1495, applied to multiple solid tumors; and a TREX-1 inhibitor. Operations center on advancing these candidates through clinical development.

Who are the top competitors of Millendo Therapeutics?

Millendo Therapeutics's top competitors include Moderna, BeiGene and Strand Therapeutics.

How many acquisitions has Millendo Therapeutics made?

Millendo Therapeutics has made 1 acquisition, including Alizé Pharma.

Who are Millendo Therapeutics's investors?

Millendo Therapeutics has 10 investors. Key investors include University of Michigan, Frazier Healthcare Partners, NEA, 5AM Ventures, and Renaissance Venture Capital Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available